Pharmacopsychiatry

Covering all new advances in the field of psychotropic drugs, we provide psychiatrists, neuroscientists, and clinicians with key clinical insights.

[Pharmacopsychiatry @Pharmacopsy]

Going forward, news, article alerts, and more will be posted on our Linkedin and Bluesky accounts at https://t.co/OSM7vxSkSY https://t.co/E6MDOFWk5E
Be sure to connect with us, follow, comment, and repost!

[Pharmacopsychiatry @Pharmacopsy]

Inflammation has been implicated in psychiatric disease and medication response. In this recent paper, a higher placebo effect was noted in individuals with low-grade inflammation compared to ketamine.
https://t.co/3lZy91uJ35

[Pharmacopsychiatry @Pharmacopsy]

Individuals with affective disorders exposed to psychotropic medications had a lower risk of colorectal cancer in this recent analysis. Role for #pharmacomicrobiomics?

https://t.co/gNdNrGl6op

[Pharmacopsychiatry @Pharmacopsy]

An LTE from Ferreira et al. provides interesting discussion points regarding recent publication on pentoxifylline as an augementation treatment in depression. Read more here:

https://t.co/q7cwj9U5xo

[Pharmacopsychiatry @Pharmacopsy]

This study found no difference in weight gain and psychopathology between inpatients with anorexia nervosa receiving antipsychotics compared to not. Interestingly, newly initiated patients did have greater weight gain compared to continued treatment.

https://t.co/EeUPZsI6Tw

[Pharmacopsychiatry @Pharmacopsy]

Currently, we cannot determine the risk of treatment resistance in patients with first episode psychosis, however, this study found that specific factors may help to make this prediction, including LOS and number of antipsychotics.

https://t.co/F2X0EfXNzc

[Pharmacopsychiatry @Pharmacopsy]

It is well known that stress can potentiate depressive symptoms. In mice, NOX2 was a pivotal player in depressive symptoms and blocking NOX2 alleviated symptoms. Is NOX2 a future therapeutic target for depression?

https://t.co/bC1M49k2r2

[Pharmacopsychiatry @Pharmacopsy]

Pgp is a fascinating family that could play a role in response to antidepressants. This study showed one variant specifically affects cognitive response to antidepressants. Check it out here:

https://t.co/QqJixTd7e1

[Pharmacopsychiatry @Pharmacopsy]

Deprescribing is a complicated and underappreciated aspect of treatment. @JKEserian and team reviewed 47 cases/series of drug withdrawal and found that adverse events were the #1 reason for discontinuation. Large-scale studies of deprescribing are needed.
https://t.co/Jajw6iWnFC

[Pharmacopsychiatry @Pharmacopsy]

This 21 year real world study of antipsychotic prescriptions showed greatest persistance with clozapine but due to its high risk of side effects, SGAs such as olanzapine (with lower persistance) were more commonly prescribed.

https://t.co/LcLi5SvEyV

[Pharmacopsychiatry @Pharmacopsy]

Switching from tobacco to e-cigarettes is a controversial option to reduce smoking in individuals undergoing opioid treatment, however, a survey in 2014 and 2021 did not show a significance switchover in patients.
https://t.co/uSGOk38gyO

[Pharmacopsychiatry @Pharmacopsy]

Repurposing antidepressants for COVID is new frontier, Bonnet and Juckel's LTE call for the consideration of fluvoxamine for COVID treatment, especially in areas with few other treatments.

https://t.co/RYB3D0bFpg

[Pharmacopsychiatry @Pharmacopsy]

Using the patient state index to measure anesthetic depth in ECT resulted in better seizure quality and helped determine optimal electrical stimulus time but did not improve cognitive impairment.
https://t.co/kr03ZfcclF

[Pharmacopsychiatry @Pharmacopsy]

Keep an eye out for a new feasibility study comparing efficacy of ECT vs aripiprazole in treating patients with clozapine-resistant schizophrenia spectrum disorders. Check out the planned methodology here:

https://t.co/5U0di9Lahu

[Pharmacopsychiatry @Pharmacopsy]

Variants in DRD2 and DRD3 may play a role in risk for adverse events with amisulpride, adding to the intricate PGx story for antipsychotics.

https://t.co/1outgHB3PU

[Pharmacopsychiatry @Pharmacopsy]

@shakilameshkat and team found that individuals with depression were 7.3x more likely to report memory issues than those without MDD. Also, individuals taking TCAs were most likely to have memory issues.

https://t.co/dQQ2RtWKy6

[Pharmacopsychiatry @Pharmacopsy]

This massive review and retrospective analysis out of Germany found that lithium use decreased over 25 years in various psychiatric diseases. Read more here:

https://t.co/80lkBUX1Ij

[Pharmacopsychiatry @Pharmacopsy]

Could targeting the HPA-axis be anew therapeutic option for personalizing treatment for MDD and anxiety? Check out this review exploring the possibility:

https://t.co/rPgKZrkFLv

[Pharmacopsychiatry @Pharmacopsy]

New @CANBIND data hot off the press! Authors found that CYP2C19 rs4244285 was associated with weight gain in IM and NMs but not PMs, suggesting a biomarker and functional target for understanding antidepressant weight gain.

https://t.co/UFWgq9djnu

[Pharmacopsychiatry @Pharmacopsy]

Off-label antipsychotic use in BPSD can have severe AEs. This study showed that most patients have a reduction in dose or discontinuation by 3 months post-initiation, suggesting the importance of tailoring treatment to specific patients. #BPSD

https://t.co/pAnqZ3N98j